Loading...
OTCM
HLBBF
Market cap5.44bUSD
Jun 17, Last price  
6.60USD
1D
-9.47%
1Q
15.79%
Name

H. Lundbeck

Chart & Performance

D1W1MN
OTCM:HLBBF chart
P/E
13.59
P/S
1.94
EPS
3.17
Div Yield, %
1.56%
Shrs. gr., 5y
4.52%
Rev. gr., 5y
4.86%
Revenues
22.00b
+10.51%
9,069,800,0009,221,000,00010,984,900,00011,281,800,00013,747,000,00014,765,000,00016,007,000,00014,802,000,00015,258,000,00013,468,000,00014,594,000,00015,634,000,00017,234,000,00017,875,000,00017,358,000,00017,667,000,00016,299,000,00018,246,000,00019,912,000,00022,004,000,000
Net income
3.14b
+37.25%
2,923,400,0002,158,700,0003,353,500,0002,736,200,0002,007,000,0002,466,000,0002,282,000,0001,107,000,000855,000,000-153,000,000-5,694,000,0001,211,000,0002,624,000,0003,907,000,0002,667,000,0001,581,000,0001,318,000,0001,916,000,0002,290,000,0003,143,000,000
CFO
3.33b
-18.48%
2,071,500,0001,394,000,0002,704,800,0002,780,200,0003,034,000,0003,265,000,0003,624,000,0002,112,000,0003,760,000,0001,610,000,000197,000,0003,126,000,0004,045,000,0005,981,000,0002,609,000,0003,837,000,0002,272,000,0003,519,000,0004,080,000,0003,326,000,000
Dividend
Mar 21, 20240.103 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Established in 1915 and headquartered in Valby, Denmark, H. Lundbeck A/S is a global biopharmaceutical company dedicated to the research, development, production, and sale of innovative pharmaceuticals. Its core mission is to provide treatments for psychiatric and neurological disorders across Europe, the United States, and international markets. Key therapeutic offerings include Abilify Maintena for schizophrenia, Brintellix/Trintellix for depression, Northera addressing symptomatic neurogenic orthostatic hypotension, Vyepti for migraine prevention, and Rexulti/Rxulti, which treats both depression and schizophrenia. The company's portfolio further encompasses Azilect for Parkinson's disease, Cipralex/Lexapro to manage depression, Ebixa for Alzheimer's disease, Onfi for Lennox-Gastaut syndrome, Sabril for epilepsy, and Xenazine for chorea associated with Huntington's disease, among other vital medications. Lundbeck distributes its products primarily through pharmaceutical distributors, pharmacies, and hospitals. Strategic alliances are integral to its operations, including a collaboration with Otsuka Pharmaceuticals Co., Ltd., a partnership with FeetMe focused on sensor shoe sole technology, and an agreement with Alloy Therapeutics, Inc. for advancing the discovery of novel biologic therapies.
URL
https://www.lundbeck.com/
IPO date
Jan 01, 1999
Employees
5,600
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT